Asensus Surgical
ASXC

$0.34

0.5%

Market Cap: 92.4M

About: Asensus Surgical Inc is a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seeks to address the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System is the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world. The company's single segment includes the research, development, and sale of medical device robotics to improve minimally invasive surgery.

Employees: 209

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 3 analysts

0

News positive %

of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0.88% less ownership

Funds ownership: 9.78% [Q4 2023] → 8.9% (-0.88%) [Q1 2024]

3% less funds holding

Funds holding: 71 [Q4 2023] → 69 (-2) [Q1 2024]

13% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 15

32% less capital invested

Capital invested by funds: $8.25M [Q4 2023] → $5.57M (-$2.67M) [Q1 2024]

40% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 20

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$0.35

3%

upside

Avg. target

$0.90

165%

upside

High target

$2

490%

upside

3 analyst ratings

1 positive

33%

2 neutral

67%

0 negative

0%

HC Wainwright & Co. Swayampakula Ramakanth	3%upside $0.35	Neutral Reiterated	16 May 2024
HC Wainwright & Co. Swayampakula Ramakanth	3%upside $0.35	Neutral Downgraded	4 Apr 2024
HC Wainwright & Co. Swayampakula Ramakanth	490%upside $2	Buy Maintained	22 Mar 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about ASXC published over the past 30 days

Asensus Surgical Announces The Rocky Mountain Hospital for Children in Denver, Colorado to Initiate Senhance Surgery Program

First Senhance® System placement at a dedicated pediatric hospital in the United States First Senhance® System placement at a dedicated pediatric hospital in the United States

Asensus Surgical Announces The Rocky Mountain Hospital for Children in Denver, Colorado to Initiate Senhance Surgery Program

Asensus Surgical Receives FDA 510(k) Clearance for Senhance Surgical System in Urology

RESEARCH TRIANGLE PARK, N.C., July 23, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for an expanded indication to treat adult and pediatric Urology patients with the Senhance® Surgical System.

Asensus Surgical Receives FDA 510(k) Clearance for Senhance Surgical System in Urology

Asensus Surgical Announces LKH-Universitätsklinikum Graz Hospital in Austria to Initiate Senhance Surgery Program

RESEARCH TRIANGLE PARK, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient, announced that LKH-Universitätsklinikum Graz in Austria has entered into an agreement to lease and utilize a Senhance® Surgical System.

Asensus Surgical Announces LKH-Universitätsklinikum Graz Hospital in Austria to Initiate Senhance Surgery Program

Zacks Investment Research

Asensus Surgical (ASXC) Announces New Hospital Tie-Up on Senhance

Asensus Surgical (ASXC) announces an agreement with St. Marianna University School of Medicine Yokohama City Seibu Hospital to lease its Senhance Surgical System.

Asensus Surgical (ASXC) Announces New Hospital Tie-Up on Senhance

Asensus Surgical Announces St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan to Initiate Senhance Surgery Program

RESEARCH TRIANGLE PARK, N.C., June 24, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, today announced that St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan has entered into an agreement to lease and utilize a Senhance® Surgical System in the Urology and Gastroenterology/General Surgery department.

Asensus Surgical Announces St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan to Initiate Senhance Surgery Program

Zacks Investment Research

Asensus Surgical (ASXC) Inks a Merger Agreement With KARL STORZ

KARL STORZ is set to acquire all of the outstanding shares of Asensus Surgical (ASXC) for $0.35 per share in cash, making Asensus a subsidiary of KARL STORZ.

Asensus Surgical (ASXC) Inks a Merger Agreement With KARL STORZ

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, ASXC on Behalf of Shareholders

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, ASXC on Behalf of Shareholders

ASENSUS SURGICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Asensus Surgical, Inc. - ASXC

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Asensus Surgical, Inc. (NYSE: ASXC) to KARL STORZ Endoscopy-America, Inc. Under the terms of the proposed transaction, shareholders of Asensus will receive $0.35 in cash for each share of Asensus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

ASENSUS SURGICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Asensus Surgical, Inc. - ASXC

SHAREHOLDER ALERT: The M&A Class Action Investigates the Merger of Asensus Surgical, Inc. - ASXC

NEW YORK , June 7, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Asensus Surgical, Inc. (NYSE: ASXC ), relating to its proposed merger with KARL STORZ Endoscopy-America, Inc., a wholly owned direct subsidiary of KARL STORZ SE & Co. KG.

SHAREHOLDER ALERT: The M&A Class Action Investigates the Merger of Asensus Surgical, Inc. - ASXC

Shareholder Alert: Ademi LLP investigates whether Asensus Surgical, Inc. has obtained a Fair Price for its Public Shareholders

MILWAUKEE, June 7, 2024 /PRNewswire/ -- Ademi LLP is investigating Asensus Surgical (NYSE: ASXC) for possible breaches of fiduciary duty and other violations of law in its transaction with KARL STORZ Click here to learn how to join the investigation: https://www.ademilaw.com/case/asensus-surgical-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

Shareholder Alert: Ademi LLP investigates whether Asensus Surgical, Inc. has obtained a Fair Price for its Public Shareholders

See News Rankings